HIT Consultant April 4, 2024
What You Should Know:
– Biolinq, a provider of precision wearable biosensors for metabolic health secures $58M led by Alpha Wave Ventures. The round will include participation from Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures and existing investors RiverVest Venture Partners, AXA IM Alts, Global Health Investment Corporation, Aphelion Capital, Senvest Management, Features Capital and Taisho Pharmaceutical. J.P. Morgan served as a placement agent to Biolinq in connection with the financing.
– The funding will propel Biolinq towards completion of a pivotal clinical trial in the US and subsequent FDA submission for its innovative continuous glucose monitoring (CGM) patch.
Biolinq’s Intradermal Sensor
The Biolinq patch offers a unique approach to glucose monitoring:
- Simple and Discreet:...
Today's Sponsors
Today's Sponsor